Genmab — Maj 2018
-
Please give me som new ones.

-
Sydbank: Pipeline-potentialet i Genmab er ikke afspejlet i kursen
Mens forventningerne til guldægget Darzalex efterhånden er solidt indarbejdet i den nuværende kurs for Genmab-aktien, så bliver potentialet for resten af biotekselskabets pipeline endnu ikke afspejlet i prisen.
(medwatch.dk)
-
Jeg tror ikke at der er nogen analytikere som er skuffet over regnskabet.
-
Det har du ret JKY. Fred være med det.
-
BMS checkmate 142 er fuldt rekruteret https://clinicaltrials.gov/ct2/show/NCT02060188?term=CheckMate142&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind